Articles
Amplifica, a clinical-stage biopharmaceutical company based in San Diego, has announced the results from its first-in-human trial of AMP-303, an intradermal injection treatment for androgenic alopecia (AGA). Amplifica has several AGA treatments in the pipeline, including AMP-203 (osteopontin) and AMP-601 (SCUBE3). What is AMP-303? We spoke about AMP-303 last year when they announced the initiation…
A recent press release from Elevai Labs noted “encouraging data results” from a study conducted by its subsidiary, Elevai Skincare Inc. We don’t have the full details of the study, but it was mentioned in the press release that it is an ongoing study in which patients with androgenic alopecia were treated with Elevai Exosomes.…
The US Food and Drug Administration (FDA) has recently approved deuruxolitinib, an oral Janus Kinase (JAK) inhibitor developed by Sun Pharma, for treating severe alopecia areata in adults. What is Deuruxolitinib? Deuruxolitinib, sold under the brand name Leqselvi, is an oral JAK inhibitor that selectively targets JAK1 and JAK2, proteins involved in the immune signaling…
Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men. What is DLQ01? DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation…
There is more news in the androgenic alopecia space, as Eirion Therapeutics begins a Phase 1 trial for ET-02, a topical treatment. What is ET-02? According to Eirion Therapeutics, ET-02 works by targeting hair follicle stem cells that have become defective or inactive in individuals suffering from androgenic alopecia, enabling hair follicles to resume normal…
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Equillium, a clinical-stage biotechnology company, has reported its findings from a phase 2 study of EQ101, a new treatment for patients with moderate to severe alopecia areata (AA). What is EQ101? EQ101 is a first-in-class, selective, tri-specific inhibitor that targets IL-2, IL-9, and IL-15 proteins involved in the immune response. These proteins have been implicated…
Lumenis Be. Ltd, an energy-based medical device company specializing in aesthetic and eye care solutions, has introduced FoLix™, a fractional laser system for treating hair loss. Recently cleared by the FDA, FoLix is the first fractional laser to be cleared for hair loss treatment for both women and men in the United States. What is…
Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). What is STS-01? STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting…
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…